Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
41
Recruiting, any sponsor type, condition "idiopathic pulmonary fibrosis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed211
41 trials
Showing 1 to 25, recently updated first.
Oorja Bio, Inc.Industry
NCT07869147 · 95 participants (planned) · Start Nov 2026 · Primary completion Jan 2029
Drug: ORJ-001 · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Doral, Florida; DuBois, Pennsylvania
- Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Contineum TherapeuticsIndustry
NCT07284459 · 324 participants (planned) · Start Jan 8, 2026 · Primary completion May 2028
Drug: PIPE-791 Dose A; PIPE-791 Dose B and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Mar del Plata, Argentina; Quilmes, Argentina; Buenos Aires, Argentina · 113 sites in all
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsPivotal-lookingRecruiting
Trevi TherapeuticsIndustry
NCT07868419 · 201 participants (planned) · Start Sep 30, 2026 · Primary completion Aug 2027
Drug: NAL ER; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Tuscaloosa, Alabama; New Britain, Connecticut; Wilmington, Delaware · 16 sites in all
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsPivotal-lookingRecruiting
Trevi TherapeuticsIndustry
NCT07671911 · 306 participants (planned) · Start Jun 29, 2026 · Primary completion Jun 2028
Drug: NAL ER; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Newport Beach, California; Palm Springs, California; Redding, California · 32 sites in all
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Rein TherapeuticsIndustry
NCT06968845 · 120 participants (planned) · Start Feb 2, 2026 · Primary completion Sep 30, 2027
Drug: LTI-03; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 48 sites in all
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07002034 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: RE104 for Injection · For: Adjustment Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 33 sites in all
- Senicapoc in Patients With Worsening Fibrotic Interstitial Lung DiseasePivotal-lookingRecruiting
Vejle HospitalAcademic, hospital or other
NCT06714123 · 140 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 2028
Drug: Senicapoc; Placebo · For: Pulmonary Fibrosis, Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis
Sites: Aarhus N, Denmark; Copenhagen, Denmark; Tartu, Estonia · 5 sites in all
Avraham UntermanAcademic, hospital or other
NCT07919015 · 70 participants (planned) · Start Feb 1, 2026 · Primary completion Jun 30, 2027
Drug: Nerandomilast · For: Idiopathic Pulmonary Fibrosis (IPF); Progressive Pulmonary Fibrosis
Sites: Ashkelon, Israel; Haifa, Israel; Ramat Gan, Israel · 4 sites in all
- A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07652658 · 359 participants (planned) · Start Jun 11, 2026 · Primary completion Sep 18, 2028
Drug: AZD8965 low dose; AZD8965 medium dose and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Birmingham, Alabama; Phoenix, Arizona; Loma Linda, California · 198 sites in all
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
PureTechIndustry
NCT07284602 · 1,100 participants (planned) · Start Jun 26, 2026 · Primary completion Nov 2029
Drug: Deupirfenidone; Pirfenidone (PFD) · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Palm Spring, California; Redding, California; Hialeah, Florida · 18 sites in all
- A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07516951 · 240 participants (planned) · Start Jul 8, 2026 · Primary completion Jun 27, 2028
Drug: CHF10067; CHF10067 · For: Idiopathic Pulmonary Fibrosis
Sites: Dothan, Alabama; St. Petersburg, Florida; Hannibal, Missouri · 19 sites in all
- Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPFPivotal-lookingRecruiting
Henan University of Traditional Chinese MedicineAcademic, hospital or other
NCT06914713 · 384 participants (planned) · Start Sep 8, 2025 · Primary completion Dec 30, 2027
Drug: Jin-shui Huan-xian granule; Jin-shui Huan-xian granule placebo · For: Idiopathic Pulmonary Fibrosis(IPF)
Sites: Zhengzhou, China
- AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFPivotal-lookingRecruiting
Avalyn Pharma Inc.Industry
NCT07194382 · 160 participants (planned) · Start Mar 10, 2026 · Primary completion Dec 2026
Drug: AP02; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Camperdown, Australia; Kingswood, Australia; New Lambton Heights, Australia · 49 sites in all
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
InSilico Medicine Hong Kong LimitedIndustry
NCT07687459 · 320 participants (planned) · Start Sep 9, 2026 · Primary completion Oct 30, 2029
Drug: INS018_055 tablets; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Hefei, China; Beijing, China; Fuzhou, China · 47 sites in all
- Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Mannkind CorporationIndustry
NCT07679893 · 153 participants (planned) · Start May 15, 2026 · Primary completion Dec 30, 2027
Drug: Nintedanib Dry Powder Inhalation; Placebo · For: Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
Sites: Windsor, Canada
- Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07230288 · 165 participants (planned) · Start Jan 23, 2026 · Primary completion Sep 2029
Drug: ABBV-142; Placebo for ABBV-142 · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Dothan, Alabama; Kissimmee, Florida · 57 sites in all
- Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
Cumberland PharmaceuticalsIndustry
NCT05571059 · 128 participants (planned) · Start Jan 31, 2024 · Primary completion Jan 2028
Drug: Ifetroban Sodium; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: La Mesa, California; San Francisco, California; Farmington, Connecticut · 20 sites in all
Shanghai Synvida Biotechnology Co.,Ltd.Industry
NCT06267183 · 53 participants (planned) · Start Jan 12, 2024 · Primary completion Nov 30, 2026
Drug: SV001; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Shanghai, China
University of Alabama at BirminghamAcademic, hospital or other
NCT04362644 · 10 participants (planned) · Start Dec 8, 2020 · Primary completion Jun 2027
Drug: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714 · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama
Joseph C. WuAcademic, hospital or other
NCT05988463 · 15 participants (planned) · Start Aug 1, 2026 · Primary completion Nov 1, 2028
Drug: Artesuante · For: Idiopathic Pulmonary Fibrosis
Sites: Stanford, California
National Institute of Environmental Health Sciences (NIEHS)NIH
NCT06325696 · 37 participants (planned) · Start May 5, 2025 · Primary completion Dec 31, 2027
Drug: hymecromone · For: Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial
Sites: Research Triangle Park, North Carolina
Peter CaravanAcademic, hospital or other
NCT07572383 · 15 participants (planned) · Start May 14, 2026 · Primary completion Dec 31, 2028
Drug: [68Ga]CBP8; Gadoterate Meglumine · For: Interstitial Lung Disease; Pulmonary Fibrosis
Sites: Boston, Massachusetts
University of British ColumbiaAcademic, hospital or other
NCT03800017 · 40 participants (planned) · Start Aug 7, 2024 · Primary completion Dec 31, 2026
Drug: Hyperoxia · For: Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Hypersensitivity Pneumonitis and 2 more
Sites: Vancouver, Canada
Endeavor Biomedicines, Inc.Industry
NCT07454291 · 57 participants (planned) · Start Apr 28, 2026 · Primary completion Oct 2026
Drug: taladegib; nintedanib and 2 more · For: Idiopathic Pulmonary Fibrosis
Sites: Brisbane, Australia; Melbourne, Australia
Dragonboat Biopharmaceutical Company LimitedIndustry
NCT07447102 · 96 participants (planned) · Start Apr 27, 2026 · Primary completion Apr 1, 2029
Drug: BC006; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.